At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 306 enrolled
Drug / intervention
Ergoferon +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicentre Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Safety and Clinical Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Children
In Brief
A Phase 3 clinical trial evaluating Ergoferon and Placebo for Acute Upper Respiratory Tract Infections. Completed, enrolled 306 participants across 11 sites.
Detailed Summary
The purpose of this study is: * to assess safety of the liquid dosage form of Ergoferon for treatment of acute upper respiratory tract infections in children; * to assess clinical efficacy of the liquid dosage form of Ergoferon for treatment acute upper respiratory tract infections in children.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Upper Respiratory Tract Infections
CountriesRussia
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2013
First PostedMay 2013
Primary CompletionMar 2015
TodayJul 2026
First PostedMay 1, 2013
Enrollment StartApr 1, 2013
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 13.2 years ago
Interventions
Ergoferondrug
Safety and Efficiency of liquid dosage form
Placebodrug
Safety and Efficiency of liquid dosage form